Enveloped virus-like particle expression of human cytomegalovirus glycoprotein B antigen induces antibodies with potent and broad neutralizing activity

Clinical and Vaccine Immunology

Volumn 21, Issue 2, 2014, Pages 174-180

  Kirchmeier, Marc ^a   Fluckiger, Anne Catherine ^b   Soare, Catalina ^a   Bozic, Jasminka ^a   Ontsouka, Barthelemy ^a   Ahmed, Tanvir ^a   Diress, Abebaw ^a   Pereira, Lenore ^c   Schod̈el, Florian ^d   Plotkin, Stanley ^e   Dalba, Charlotte ^a   Klatzmann, David ^f,g,h,i   Anderson, David E ^a  

^a VBI Vaccines   (United States)

^b Bionaria ^*  (France)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Philimmune LLC   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f SORBONNE UNIVERSITÉ   (France)

^g CNRS   (France)

^h INSERM   (France)

ⁱ PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; CYTOMEGALOVIRUS VACCINES; EPITHELIAL CELLS; FEMALE; MICE; MICE, INBRED BALB C; VACCINES, VIRUS-LIKE PARTICLE; VIRAL ENVELOPE PROTEINS;

EID: 84893224666     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00662-13     Document Type: Article

References (23)

1. Stratton KR, Durch J, Lawrence RS. 2000. Vaccines for the 21st century: a tool for decisionmaking. Committee to Study Priorities for Vaccine Development, Division of Health Promotion and Disease Prevention, Institute of Medicine, National Academy Press, Washington, DC.
2. Fishman JA. 2007. Infection in solid-organ transplant recipients. N. Engl. J. Med. 357:2601-2614. http://dx.doi.org/10.1056/NEJMra064928. (Pubitemid 350294226)
3. Adler SP. 2008. Human CMV vaccine trials: what if CMV caused a rash? J. Clin. Virol. 41:231-236. http://dx.doi.org/10.1016/j.jcv.2007.11.008.
4. Plotkin SA. 2002. Is there a formula for an effective CMV vaccine? J. Clin. Virol. 25(Suppl 2):S13-S21. http://dx.doi.org/10.1016/S1386-6532(02)00093- 8 (Pubitemid 35287188)
5. Pass RF, Zhang C, Evans A, Simpson T, Andrews W, Huang ML, Corey L, Hill J, Davis E, Flanigan C, Cloud G. 2009. Vaccine prevention of maternal cytomegalovirus infection. N. Engl. J. Med. 360:1191-1199. http://dx.doi.org/10. 1056/NEJMoa0804749.
6. Griffiths PD, Stanton A, McCarrell E, Smith C, Osman M, Harber M, Davenport A, Jones G, Wheeler DC, O'Beirne J, Thorburn D, Patch D, Atkinson CE, Pichon S, Sweny P, Lanzman M, Woodford E, Rothwell E, Old N, Kinyanjui R, Haque T, Atabani S, Luck S, Prideaux S, Milne RS, Emery VC, Burroughs AK. 2011. Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial. Lancet 377:1256-1263. http://dx.doi.org/10.1016/S0140-6736(11)60136-0.
7. Lilja AE, Mason PW. 2012. The next generation recombinant human cytomegalovirus vaccine candidates-beyond gB. Vaccine 30:6980-6990. http://dx.doi.org/10.1016/j.vaccine.2012.09.056.
8. Cui X, Meza BP, Adler SP, McVoy MA. 2008. Cytomegalovirus vaccines fail to induce epithelial entry neutralizing antibodies comparable to natural infection. Vaccine 26:5760-5766. http://dx.doi.org/10.1016/j.vaccine.2008.07. 092.
9. Wang D, Li F, Freed DC, Finnefrock AC, Tang A, Grimes SN, Casimiro DR, Fu TM. 2011. Quantitative analysis of neutralizing antibody response to human cytomegalovirus in natural infection. Vaccine 29:9075-9080. http://dx.doi.org/ 10.1016/j.vaccine.2011.09.056.
10. Fu TM, Wang D, Freed DC, Tang A, Li F, He X, Cole S, Dubey S, Finnefrock AC, ter Meulen J, Shiver JW, Casimiro DR. 2012. Restoration of viral epithelial tropism improves immunogenicity in rabbits and rhesus macaques for a whole virion vaccine of human cytomegalovirus. Vaccine 30:7469-7474. http://dx.doi.org/10.1016/j.vaccine.2012.10.053.
11. Loomis RJ, Lilja AE, Monroe J, Balabanis KA, Brito LA, Palladino G, Franti M, Mandl CW, Barnett SW, Mason PW. 2013. Vectored codelivery of human cytomegalovirus gH and gL proteins elicits potent complement-independent neutralizing antibodies. Vaccine 31:919-926. http://dx.doi.org/10.1016/j. vaccine.2012.12.009.
12. Macagno A, Bernasconi NL, Vanzetta F, Dander E, Sarasini A, Revello MG, Gerna G, Sallusto F, Lanzavecchia A. 2010. Isolation of human monoclonal antibodies that potently neutralize human cytomegalovirus infection by targeting different epitopes on the gH/gL/UL128-131A complex. J. Virol. 84:1005-1013. http://dx.doi.org/10.1128/JVI.01809-09.
13. Axelsson F, Adler SP, Lamarre A, Ohlin M. 2007. Humoral immunity targeting site I of antigenic domain 2 of glycoprotein B upon immunization with different cytomegalovirus candidate vaccines. Vaccine 26:41-46. http://dx.doi.org/10.1016/j.vaccine.2007.10.048. (Pubitemid 350213210)
14. Garrone P, Fluckiger AC, Mangeot PE, Gauthier E, Dupeyrot-Lacas P, Mancip J, Cangialosi A, Du Chéné I, LeGrand R, Mangeot I, Lavillette D, Bellier B, Cosset FL, Tangy F, Klatzmann D, Dalba C. 2011. A prime-boost strategy using virus-like particles pseudotyped for HCV proteins triggers broadly neutralizing antibodies in macaques. Sci. Transl. Med. 328: 94ra71 http://dx.doi.org/10.1126/scitranslmed.3002330.
15. Sampaio KL, Cavignac Y, Stierhof YD, Sinzger C. 2005. Human cytomegalovirus labeled with green fluorescent protein for live analysis of intracellular particle movements. J. Virol. 79:2754-2767. http://dx.doi.org/10. 1128/JVI.79.5.2754-2767.2005. (Pubitemid 40270553)
16. Wang D, Shenk T. 2005. Human cytomegalovirus virion protein complex required for epithelial and endothelial cell tropism. Proc. Natl. Acad. Sci. U. S. A. 102:18153-18158. http://dx.doi.org/10.1073/pnas.0509201102. (Pubitemid 41798517)
17. Cui X, Lee R, Adler SP, McVoy MA. 2013. Antibody inhibition of human cytomegalovirus spread in epithelial cell cultures. J. Virol. Methods 192:44-50. http://dx.doi.org/10.1016/j.jviromet.2013.04.015.
18. Sharma S, Wisner TW, Johnson DC, Heldwein EE. 2013. HCMV gB shares structural and functional properties with gB proteins from other herpesviruses. Virology 435:239-249. http://dx.doi.org/10.1016/j.virol.2012.09.024.
19. Garcia NJ, Chen J, Longnecker R. 2013. Modulation of Epstein-Barr virus glycoprotein B (gB) fusion activity by the gB cytoplasmic tail domain. mBio. 4(1):e00571-12. http://dx.doi.org/10.1128/mBio.00571-12.
20. Tugizov S, Navarro D, Paz P, Wang Y, Qadri I, Pereira L. 1994. Function of human cytomegalovirus glycoprotein B: syncytium formation in cells constitutively expressing gB is blocked by virus-neutralizing antibodies. Virology 201:263-276. http://dx.doi.org/10.1006/viro.1994.1291. (Pubitemid 24187271)
21. Becke S, Aue S, Thomas D, Schader S, Podlech J, Bopp T, Sedmak T, Wolfrum U, Plachter B, Reyda S. 2010. Optimized recombinant dense bodies of human cytomegalovirus efficiently prime virus specific lymphocytes and neutralizing antibodies without the addition of adjuvant. Vaccine 28:6191-6198. http://dx.doi.org/10.1016/j.vaccine.2010.07.016.
22. Cayatte C, Schneider-Ohrum K, Wang Z, Irrinki A, Nguyen N, Lu J, Nelson C, Servat E, Gemmell L, Citkowicz A, Liu Y, Hayes G, Woo J, Van Nest G, Jin H, Duke G, McCormick AL. 2013. Cytomegalovirus vaccine strain Towne-derived dense bodies induce broad cellular immune responses and neutralizing antibodies that prevent infection of fibroblasts and epithelial cells. J. Virol. 87:11107-11120. http://dx.doi.org/10.1128/JVI.01554-13.
23. Deml L, Speth C, Dierich MP, Wolf H, Wagner R. 2005. Recombinant HIV-1 Pr55gag virus-like particles: potent stimulators of innate and acquired immune responses. Mol. Immunol. 42:259-277. http://dx.doi.org/10.1016/j.molimm.2004.06. 028. (Pubitemid 39361454)